Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.78 +2.12 (+1.65%)
Streaming Delayed Price Updated: 12:42 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,717,846
Open 128.88
Bid (Size) 130.77 (1)
Ask (Size) 130.78 (1)
Prev. Close 128.66
Today's Range 128.72 - 130.82
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.23%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Merck halts vibostolimab and pembrolizumab coformulation arm in KeyVibe-010 Phase 3 trial for high-risk melanoma due to higher discontinuation rates and immune-related adverse events. 
Via Benzinga

Performance

YTD
+15.49%
+15.49%
1 Month
+3.64%
+3.64%
3 Month
+4.27%
+4.27%
6 Month
+28.00%
+28.00%
1 Year
+19.54%
+19.54%

More News

Read More
Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma
From Merck & Co., Inc.
Via Business Wire
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Healthcare And Biotech Investing 101: What You Need To Know.
Via Talk Markets
Topics Stocks
Exposures US Equities
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Via Benzinga
3 Biotech Stocks to Sell in May Before They Crash & Burn
Via InvestorPlace
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
Via InvestorPlace
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
From Merck & Co., Inc.
Via Business Wire
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Merck to Participate in the Bank of America Securities 2024 Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Via Benzinga
Topics Economy
Exposures Economy
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks to Double Your Money in the Next 24 Months
Via InvestorPlace
In a market where value is scarce, NYSE:MRK offers a refreshing opportunity with its solid fundamentals.
Via Chartmill
Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio's Bladder Cancer Combo Therapy
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival (OS) as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults
From Merck & Co., Inc.
Via Business Wire
Pharma Stock Roundup: Merck, Sanofi, AstraZeneca, Novartis' Q1 Results, Pipeline & Regulatory Updates
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.